nivisnebart 
GtoPdb Ligand ID: 13797
|
Compound class:
Antibody
Comment: Nivisnebart is an anti-sortilin 1 (SORT1) monoclonal antibody. It was developed for potential to treat neurodegenerative diseases. SORT1 down-regulation is proposed as a mechanism to elevate progranulin (PGRN) levels for therapeutic benefit in frontotemporal dementia patients with granulin precursor (GRN) mutations [1]. This mechanistic approach is also considered relevant to more prevalent neurodegenerative diseases including Alzheimer's and Parkinson's diseases. Nivisnebart is potentially the INN for Alector's second anti-SORT1 clinical candidate AL101 (a.k.a. GSK4527226), that is in phase 2 clinical trial.
|
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License